{"title":"Clozapine is not the end of the story","authors":"Lawrence H. Price M.D.","doi":"10.1002/pu.31134","DOIUrl":null,"url":null,"abstract":"<p>As most <i>Update</i> readers are aware, the U.S. Food and Drug Administration (FDA) has approved only one drug with an indication for treatment-resistant schizophrenia: clozapine. You might not know the backstory to this though.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Brown University Psychopharmacology Update","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/pu.31134","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
As most Update readers are aware, the U.S. Food and Drug Administration (FDA) has approved only one drug with an indication for treatment-resistant schizophrenia: clozapine. You might not know the backstory to this though.